Episodios

  • Harvard's Dr. George Church on Aging Reversal, Woolly Mammoths, and the Future of Genomics

    Harvard's Dr. George Church on Aging Reversal, Woolly Mammoths, and the Future of Genomics
    Jul 26 2022
    Dr. George Church is a Professor of Genetics at Harvard Medical School and a co-founder of multiple biotech companies. In this wide-ranging interview, he speaks about his work on de-extinction, his vision of a future without age-related illness, and his AI-powered startups.
    Más Menos
    46 m
  • How Academia Can Make an Impact: University of Michigan's Dr. Karandeep Singh on Deployment and Evaluation

    How Academia Can Make an Impact: University of Michigan's Dr. Karandeep Singh on Deployment and Evaluation
    Jul 11 2022
    Karandeep Singh, MD, MMSc, is an Assistant Professor of Learning Health Sciences, Internal Medicine, Urology, and Information at the University of Michigan. He speaks with us about bridging the gap between academia and practice and discusses how the University of Michigan deploys and rigorously evaluates machine learning models in real clinical practice.
    Más Menos
    49 m
  • Immunai's Luis Voloch on Industrial-Scale Immunology

    Immunai's Luis Voloch on Industrial-Scale Immunology
    Jun 20 2022
    Luis Voloch is Co-Founder and Chief Technology Officer at Immunai, which is applying AI to immunology, genomics and drug discovery. He speaks with us about how Immunai is using AI to build a comprehensive, top-of-the-tree view of the immune system.
    Más Menos
    44 m
  • Changemakers and Truth-Seekers: Johns Hopkins's Dr. Suchi Saria on Bayesian Health

    Changemakers and Truth-Seekers: Johns Hopkins's Dr. Suchi Saria on Bayesian Health
    Apr 4 2022
    Dr. Suchi Saria is the Founder and CEO of Bayesian Health, the John C. Malone Associate Professor of computer science, statistics, and health policy, and the Director of the Machine Learning and Healthcare Lab at Johns Hopkins University. She speaks with us on how Bayesian Health uses insights from electronic health records to detect diseases and improve patient outcomes.
    Más Menos
    43 m
  • Medical (Incentives) Engineering: Harvard's Dr. Trishan Panch on Wellframe, Research and Entrepreneurship

    Medical (Incentives) Engineering: Harvard's Dr. Trishan Panch on Wellframe, Research and Entrepreneurship
    Mar 21 2022
    Dr. Panch is a primary care physician, the Co-Founder of Wellframe, and an instructor at the Harvard T.H. Chan School of Public Health. He speaks with us about Wellframe's work on demystifying complex care regimens, providing personalized support to patients, and understanding social issues affecting healthcare. He also discusses entrepreneurship strategies, the role of academic research, and the future of medical AI regulation.
    Más Menos
    45 m
  • The Medical AI 2x2: GV’s Dr. Krishna Yeshwant on Market Positioning and Investing

    The Medical AI 2x2: GV’s Dr. Krishna Yeshwant on Market Positioning and Investing
    Mar 7 2022
    Dr. Krishna Yeshwant is Managing Partner of GV. In addition to working with GV since its inception, he has earned degrees in computer science, medicine and business, and he practiced at Brigham and Women’s Hospital in Boston, Massachusetts for several years. He speaks with us about different segments of the healthcare market and the role of investors in improving medicine.
    Más Menos
    41 m
  • Like the Internet in 1999: Andreessen Horowitz‘s Julie Yoo on Investing and Modernizing Healthcare

    Like the Internet in 1999: Andreessen Horowitz‘s Julie Yoo on Investing and Modernizing Healthcare
    Feb 21 2022
    Julie Yoo is a General Partner at Andreessen Horowitz where she leads investments in healthcare technology. Prior to joining a16z, Julie was the co-founder, Chief Product Officer, and Board Director at Kyruus, a venture-backed health tech company recognized as a market leader in patient access. She speaks with us about opportunities in digital healthcare, Andreessen Horowitz’s approach to healthcare investing, and her journey from operator to investor.
    Más Menos
    46 m
  • Building a Bicycle: Obvious Ventures’ Nan Li on Investing and Platform Biology

    Building a Bicycle: Obvious Ventures’ Nan Li on Investing and Platform Biology
    Feb 7 2022
    Nan Li is Managing Director of Obvious Ventures, leading investments in computational biology visionaries, AI-driven platforms and intelligent robotics companies. He speaks with us on how AI and advances in physical tools are industrializing drug discovery, allowing new medicines to be found at a previously unprecedented pace.
    Más Menos
    49 m